Activation of v-Myb avian myeloblastosis viral oncogene homolog-like2 (MYBL2)-LIN9 complex contributes to human hepatocarcinogenesis and identifies a subset of hepatocellular carcinoma with mutant p53

Hepatology

Volumn 53, Issue 4, 2011, Pages 1226-1236

  Calvisi, Diego F ^a   Simile, Maria M ^a   Ladu, Sara ^a   Frau, Maddalena ^a   Evert, Matthias ^b   Tomasi, Maria L ^a   Demartis, Maria I ^a   Daino, Lucia ^a   Seddaiu, Maria A ^a   Brozzetti, Stefania ^c   Feo, Francesco ^a   Pascale, Rosa M ^a  

^a UNIVERSITY OF SASSARI   (Italy)

^b UNIVERSITY OF GREIFSWALD   (Germany)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN B1; DOXORUBICIN; MESSENGER RNA; PROTEIN; PROTEIN MYB; PROTEIN P53; RETINOBLASTOMA PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; V MYB AVIAN MYELOBLASTOSIS VIRAL ONCOGENE HOMOLOG LIKE2 PROTEIN; V MYB AVIAN MYELOBLASTOSIS VIRAL ONCOGENE HOMOLOG LIKE2 PROTEIN LIN9 PROTEIN COMPLEX;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; DNA DAMAGE; GENE MUTATION; GENE SILENCING; GENOMIC INSTABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; UPREGULATION;

CARCINOMA, HEPATOCELLULAR; CELL CYCLE PROTEINS; CELL LINE, TUMOR; DISEASE PROGRESSION; DNA DAMAGE; DOXORUBICIN; GENOMIC INSTABILITY; HUMANS; LIVER NEOPLASMS; NUCLEAR PROTEINS; TRANS-ACTIVATORS; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS; UP-REGULATION;

EID: 79953737159     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.24174     Document Type: Article

References (38)

1. Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004; 127: S5-S16.
2. Calvisi DF, Pascale RM, Feo F. Dissection of signal transduction pathways as a tool for the development of targeted therapies of hepatocellular carcinoma. Rev Recent Clin Trials 2007; 2, 217-236.
3. Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. HEPATOLOGY 2008; 48: 1312-1327.
4. Pascale RM, Simile MM, Calvisi DF, Frau M, Muroni MR, Seddaiu MA, et al. Role of HSP90, CDC37, and CRM1 as modulators of P16(INK4A) activity in rat liver carcinogenesis and human liver cancer. HEPATOLOGY 2005; 42: 1310-1319.
5. Calvisi DF, Pinna F, Ladu S, Pellegrino R, Muroni MR, Simile MM, et al. Aberrant iNOS signaling is under genetic control in rodent liver cancer and potentially prognostic for human disease. Carcinogenesis 2008; 29: 1639-1647.
6. Calvisi DF, Pinna F, Ladu S, Pellegrino R, Simile MM, Frau M, et al. Forkhead box M1B is a determinant of rat susceptibility to hepatocarcinogenesis and sustains ERK activity in human HCC. Gut 2009; 58: 679-687.
7. Calvisi DF, Pinna F, Meloni F, Ladu S, Pellegrino R, Sini M, et al. Dual-specificity phosphatase 1 ubiquitination in extracellular signal-regulated-kinase-mediated control of growth in human hepatocellular carcinoma. Cancer Res 2008; 68: 4192-4200.
8. Calvisi DF, Ladu S, Pinna F, Frau M, Tomasi ML, Sini M, et al. SKP2 and CKS1 promote degradation of cell cycle regulators and are associated with hepatocellular carcinoma prognosis. Gastroenterology 2009; 137: 1816-1826.
9. Frau M, Biasi F, Feo F, Pascale RM. Prognostic markers and putative therapeutic targets for hepatocellular carcinoma. Mol Aspects Med 2010; 31: 179-193.
10. Ramsay RG, Gonda TJ. MYB function in normal and cancer cells. Nat Rev Cancer 2008; 8: 523-534.
11. Zhu W, Giangrande PH, Nevins JR. E2Fs link the control of G1/S and G2/M transcription. EMBO J 2004; 23: 4615-4626.
12. Knight AS, Notaridou M, Watson RJ. A Lin-9 complex is recruited by MYBL2 to activate transcription of G2/M genes in undifferentiated embryonal carcinoma cells Oncogene 2009; 28: 1737-1747.
13. Forozan F, Mahlamäki EH, Monni O, Chen Y, Veldman R, Jiang Y, et al. Comparative genomic hybridization analysis of 38 breast cancer cell lines: a basis for interpreting complementary DNA microarray data. Cancer Res 2000; 60: 4519-4525.
14. Zondervan PE, Wink J, Alers JC, IJzermans JN, Schalm SW, de Man RA, et al. Molecular cytogenetic evaluation of virus-associated and non-viral hepatocellular carcinoma: analysis of 26 carcinomas and 12 concurrent dysplasias. J Pathol 2000; 192: 207-215.
15. Tanner MM, Grenman S, Koul A, Johannsson O, Meltzer P, Pejovic T, et al. Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer. Clin Cancer Res 2000; 6: 1833-1839.
16. Mao X, Orchard G, Lillington DM, Russell-Jones R, Young BD, Whittaker SJ. Amplification and overexpression of JUNB is associated with primary cutaneous T-cell lymphomas. Blood 2003; 101: 1513- 1519.
17. Nakajima T, Yasui K, Zen K, Inagaki Y, Fujii H, Minami M, et al. Activation of MYBL2 by E2F1 in hepatocellular carcinoma. Hepatol Res 2008; 38: 886-895.
18. Frau M, Ladu S, Calvisi DF, Simile MM, Bonelli P, Daino L, et al. MYBL2 expression is under genetic control and contributes to determine a hepatocellular carcinoma susceptible phenotype. J Hepatol 2010 [Epub ahead of print].
19. Mannefeld M, Klassen E, Gaubatz S. B-MYB is required for recovery from the DNA damage-induced G2 checkpoint in p53 mutant cells. Cancer Res 2009; 69: 4073-4080.
20. Calvisi DF, Donninger H, Vos MD, Birrer MJ, Gordon L, Leaner V, et al. NORE1A tumor suppressor candidate modulates p21CIP1 via p53. Cancer Res 2009; 69: 4629-4637.
21. Lee JS, Chu IS, Heo J, Calvisi DF, Sun Z, Roskams T, et al. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. HEPATOLOGY 2004; 40: 667-678.
22. Calvisi DF, Factor VM, Ladu S, Conner EA, Thorgeirsson SS. Disruption of beta-catenin pathway or genomic instability define two distinct categories of liver cancer in transgenic mice. Gastroenterology 2004; 126: 1374-86.
23. Luceri C, De Filippo C, Caderni G, Salvadori M, Giannini A, Biggeri A, et al. Detection of somatic DNA alterations in azoxymethane-induced F344 rat colon tumors by random amplified polymorphic DNA analysis. Carcinogenesis 2000; 21: 1753-6.
24. DeGregori J, Kowalik T, Nevins JR. Cellular targets for activation by the E2F1 transcription factor include DNA synthesis- and G1/S-regulatory genes. Mol Cell Biol 1995; 15: 4215-4224.
25. Pilkinton M, Sandoval R, Colamonici OR. Mammalian Mip/LIN-9 interacts with either the p107, p130/E2F4 repressor complex or B-Myb in a cell cycle-phase-dependent context distinct from the Drosophila dREAM complex. Oncogene 2007; 26: 7535-7543.
26. Schmit F, Korenjak M, Mannefeld M, Schmitt K, Franke C, von Eyss B, et al. LINC, a human complex that is related to pRB-containing complexes in invertebrates regulates the expression of G2/M genes. Cell Cycle 2007; 6: 1903-1913.
27. Charrasse S, Carena I, Brondani V, Klempnauer KH, Ferrari S. Degradation of B-Myb by ubiquitin-mediated proteolysis: involvement of the Cdc34-SCF(p45Skp2) pathway. Oncogene 2000; 19: 2986-2995.
28. Osterloh L, von Eyss B, Schmit F, Rein L, Hübner D, Samans B, et al. The human synMuv-like protein LIN-9 is required for transcription of G2-M genes and for entry into mitosis. EMBO J 2007; 26: 144-57.
29. Taylor WR, Schonthal AH, Galante J, Stark GR. p130/ E2F4 binds to and represses the cdc2 promoter in response to p53. J Biol Chem 2001; 276: 1998-2006.
30. Polager S, Ginsberg D. E2F mediates sustained G2 arrest and down-regulation of Stathmin and AIM-1 expression in response to genotoxic stress. J Biol Chem 2003; 278: 1443-9.
31. Sengupta S, Harris CC. p53: traffic cop at the crossroads of DNA repair and recombination. Nat Rev Mol Cell Biol 2005; 6: 44-55.
32. Teufel A, Staib F, Kanzler S, Weinmann A, Schulze-Bergkamen H, Galle PR. Genetics of hepatocellular carcinoma. World J Gastroenterol 2007; 13: 2271-2282.
33. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998; 282: 1497-1501.
34. Ahlbory D, Appl H, Lang D, Klempnauer KH. Disruption of B-myb in DT40 cells reveals novel function for B-Myb in the response to DNA-damage. Oncogene 2005; 24: 7127-7134.
35. Edamoto Y, Hara A, Biernat W, Terracciano L, Cathomas G, Riehle HM, et al. Alterations of RB1, p53 and Wnt pathways in hepatocellular carcinomas associated with hepatitis C, hepatitis B and alcoholic liver cirrhosis. Int J Cancer 2003; 106: 334-341.
36. Hofseth LJ, Hussain SP, Harris CC. p53: 25 years after its discovery. Trends Pharmacol Sci 2004; 25: 177-181.
37. Guan XY, Sham JS, Tai LS, Fang Y, Li H, Liang Q. Evidence for another tumor suppressor gene at 17p13.3 distal to TP53 in hepatocellular carcinoma. Cancer Genet Cytogenet 2003; 140: 45-48.
38. Yumoto Y, Hanafusa T, Hada H, Morita T, Ooguchi S, Shinji N, et al. Loss of heterozygosity and analysis of mutation of p53 in hepatocellular carcinoma. J Gastroenterol Hepatol 1995; 10: 179-185.